Background Pancreatic cancer (PC) is a highly lethal disease with few effective treatment
options. Over the past few decades, many anti‐cancer therapies have been tested in the …

Pancreatic cancer is one of the most lethal malignancies and is associated with a poor
prognosis. Surgery is considered the only potential curative treatment for pancreatic cancer …

Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease exhibiting the poorest
prognosis among solid tumors. The efficacy of conventional therapies has been hindered …

Background and Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic
chemotherapy remains the mainstream treatment for unresectable pancreatic cancer. This …

The prognosis of pancreatic ductal adenocarcinoma (PDAC), the eighth most lethal cancer
for men and ninth for women worldwide, remains dismal. The increasing rates of deaths by …

This review highlights current treatments, limitations, and pitfalls in the management of
pancreatic cancer and discusses current research in novel targets and drug development to …

Surgical resection remains the only treatment that offers a potential chance of long-term
survival. Unfortunately, about 80% of patients treated with curative intent will develop …

Importance Various first-line chemotherapy treatment regimens for patients with metastatic
pancreatic cancer have been approved in Japan, including gemcitabine (GEM); fluorouracil …

Background: Gemcitabine combined the oral fluoropyrimidine capecitabine (GemCap) is an
active antitumor therapy in the treatment of advanced or metastatic pancreatic cancer, and …